(Q37793595)

23 August 2017

title

Inhaled drug therapy for treatment of tuberculosis (English)

1 reference

23 August 2017

0 references

Amit Misra

1

1 reference

23 August 2017

Anthony J Hickey

2

1 reference

23 August 2017

Carlo Rossi

3

1 reference

23 August 2017

Gerrit Borchard

4

1 reference

23 August 2017

Hiroshi Terada

5

1 reference

23 August 2017

Kimiko Makino

6

1 reference

23 August 2017

P Bernard Fourie

7

1 reference

23 August 2017

Paolo Colombo

8

1 reference

23 August 2017

publication date

27 September 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

91

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

71-81

1 reference

Non-invasive systemic drug delivery: developability considerations for alternate routes of administration

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Human alveolar long-term clearance of ferromagnetic iron oxide microparticles in healthy and diseased subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylcholine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Pulmonary effects of chronic exposure to liposome aerosols in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Phagocytosis of liposomes by human alveolar macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Intrapulmonary deposition of aerosolized Evans blue dye and liposomes in an experimental porcine model of early ARDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Macrophages and polymorphonuclear neutrophils in lung defense and injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Alternative activation deprives macrophages of a coordinated defense program to Mycobacterium tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Uptake of inhalable microparticles affects defence responses of macrophages infected with Mycobacterium tuberculosis H37Ra.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Liquid atomizing: nebulizing and other methods of producing aerosols

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Aerosol devices and asthma therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Spacer devices for metered dose inhalers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

New treatments for chronic obstructive pulmonary disease and viable formulation/device options for inhalation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Pulmonary delivery of chitosan-DNA nanoparticles enhances the immunogenicity of a DNA vaccine encoding HLA-A*0201-restricted T-cell epitopes of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Non-invasive pulmonary aerosol delivery in mice by the endotracheal route

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

A hand-held apparatus for "nose-only" exposure of mice to inhalable microparticles as a dry powder inhalation targeting lung and airway macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Manufacture, characterization, and pharmacodynamic evaluation of engineered ipratropium bromide particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Inhaled drug delivery for tuberculosis therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Pharmaceutical particle engineering via spray drying

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Simple and scalable method for peptide inhalable powder production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Nanoparticles for drug delivery to the lungs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Trojan particles: large porous carriers of nanoparticles for drug delivery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Liposomal aerosols in the management of pulmonary infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Kinetics and toxicity of liposomal and conventional amikacin in a patient with multidrug-resistant tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Altered tissue distribution and elimination of amikacin encapsulated in unilamellar, low-clearance liposomes (MiKasome)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Development of liposomal capreomycin sulfate formulations: effects of formulation variables on peptide encapsulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Nebulization of liposome encapsulated antitubercular drugs in guinea pigs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

A review of the technical aspects of drug nebulization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Microparticle-based lung delivery of INH decreases INH metabolism and targets alveolar macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Inhalable microparticles containing large payload of anti-tuberculosis drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Fighting tuberculosis: old drugs, new formulations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Formulation strategy and use of excipients in pulmonary drug delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Effects of inhaled human insulin on airway lining fluid composition in adults with diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Evaluation of antitubercular drug-loaded surfactants as inhalable drug-delivery systems for pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Effect of mycobacterial lipids on surface properties of Curosurf: implications for lung surfactant dysfunction in tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

In vitro evaluation of inhalable isoniazid-loaded surfactant liposomes as an adjunct therapy in pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Stimulation of phagocytic activity of alveolar macrophages toward artificial microspheres by infection with mycobacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

MARCO, TLR2, and CD14 are required for macrophage cytokine responses to mycobacterial trehalose dimycolate and Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Optimum conditions for efficient phagocytosis of rifampicin-loaded PLGA microspheres by alveolar macrophages.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Phagocytic activity of alveolar macrophages toward polystyrene latex microspheres and PLGA microspheres loaded with anti-tuberculosis agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Immunization by a bacterial aerosol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Theoretical relationship of lung deposition to the fine particle fraction of inhalation aerosols.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Adjunctive salvage therapy with inhaled aminoglycosides for patients with persistent smear-positive pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Direct lung delivery of para-aminosalicylic acid by aerosol particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

A coat protein on phagosomes involved in the intracellular survival of mycobacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Lung surfactant phospholipids inhibit the uptake of respirable microspheres by the alveolar macrophage NR8383

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

The inhibition of phagocytosis of respirable microspheres by alveolar and peritoneal macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Microparticles induce variable levels of activation in macrophages infected with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Enhancement of apoptosis of THP-1 cells infected with Mycobacterium tuberculosis by inhalable microparticles and relevance to bactericidal activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Specific and non-specific phagocytosis of ligand-grafted PLGA microspheres by macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Selective delivery of rifampicin incorporated into poly(DL-lactic-co-glycolic) acid microspheres after phagocytotic uptake by alveolar macrophages, and the killing effect against intracellular Mycobacterium bovis Calmette-Guérin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Evaluation of aerosol therapy of streptomycin for tracheobronchial and pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Regional deposition of aerosolized interferon-gamma in pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Six-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Effects of aerosolized interferon-alpha in patients with pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

The role of NLRs and TLRs in the activation of the inflammasome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

NLR-mediated control of inflammasome assembly in the host response against bacterial pathogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Aerosol delivery of muramyl dipeptide to rodent lungs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Prednisone as adjunctive therapy in the management of pulmonary tuberculosis. Report of 12 cases and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Role of inhaled budesonide in the treatment of tuberculous pyrexia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Inhalational phytochemicals as possible treatment for pulmonary tuberculosis: two case reports

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Lung surfactant dysfunction in tuberculosis: effect of mycobacterial tubercular lipids on dipalmitoylphosphatidylcholine surface activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Intrapulmonary delivery of XCL1-targeting small interfering RNA in mice chronically infected with Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Interferon-gamma for respiratory diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Kinetic aspects of drug disposition in the lungs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Blood and bronchoalveolar lavage fluid acetylcholinesterase levels following microinstillation inhalation exposure to sarin in Guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Tissue concentrations: do we ever learn?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

In vivo animal models for drug delivery across the lung mucosal barrier

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Isoxyl particles for pulmonary delivery: In vitro cytotoxicity and potency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

Isoxyl aerosols for tuberculosis treatment: preparation and characterization of particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2010.08.009

10.1016/J.TUBE.2010.08.009

7 January 2021

Identifiers

DOI

1 reference

23 August 2017

1 reference